logo

For the Inventor, By the Inventor

Heidelberg, Germany

Affimed Gmbh


USPTO Granted Patents = 11

% Expired Patents = 9.1



Trademarks = 5

Forward Citations = 43

Loading Chart...
Loading Chart...

21 inventors (with patents filed for the assignee):

goldMedal Uwe Reusch (11 out of 19 patents)

silverMedal Martin Treder (8 out of 8 patents)

bronzeMedal Erich Rajkovic (7 out of 10 patents)

4.  Kristina Ellwanger (6 out of 11 patents)

5.  Ivica Fucek (6 out of 11 patents)

6.  Thorsten Ross (5 out of 5 patents)

7.  Stefan Knackmuss (5 out of 15 patents)

8.  Michael Weichel (3 out of 7 patents)

9.  Michael Tesar (3 out of 3 patents)

10.  Fabrice Le Gall (3 out of 8 patents)

11.  Sergey Kipriyanov (3 out of 5 patents)

12.  Joachim Koch (2 out of 2 patents)

13.  Karin Hoffmann (2 out of 4 patents)

14.  Melvyn Little (2 out of 23 patents)

15.  Michael Kluge (2 out of 2 patents)


11 patents:

1. 12264198 - Tandem diabody for CD16A-directed NK-cell engagement (2025-04-01),
2. 12076384 - Bispecific EGFR/CD16 antigen-binding protein (2024-09-03),
3. 11572415 - Multivalent FV antibodies (2023-02-07),
4. 11535672 - Combination of an anti-CD16A antibody with a cytokine (2022-12-27),
5. 11510972 - Bispecific EGFR/CD16 antigen-binding protein (2022-11-29),
6. 11180558 - Tandem diabody for CD16A-directed NK-cell engagement (2021-11-23),
7. 11167029 - Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy (2021-11-09),
8. 11001633 - NK cell engaging antibody fusion constructs (2021-05-11),
9. 9701750 - Anti-CD16 binding molecules (2017-07-11),
10. 9226962 - Human CD3-specific antibody with immunosuppressive properties (2016-01-05),
11. 9035026 - Anti-CD16 binding molecules (2015-05-19),
Affimed GmbH is a biotechnology company based in Heidelberg, Germany, specializing in the development of innovative immuno-oncology therapies. The company focuses on harnessing the power of the immune system to combat cancer, utilizing its proprietary platform to create bispecific antibodies and other therapeutic modalities. Affimed's research emphasizes enhancing the efficacy of cancer treatments while minimizing side effects, positioning it as a key player in the evolving landscape of cancer immunotherapy.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

11 Patents

#40 in Heidelberg

#3,521 in Germany

#51,714 in the World

Heidelberg, DE
Heidelberg, Germany

Affimed Gmbh

Forward Citations = 43

21 inventors:

goldMedal Uwe Reusch (11 out of 19 patents)

silverMedal Martin Treder (8 out of 8 patents)

bronzeMedal Erich Rajkovic (7 out of 10 patents)

4.  Kristina Ellwanger (6 out of 11 patents)

5.  Ivica Fucek (6 out of 11 patents)

Please report any incorrect information to [email protected]
Loading…